The immunoproteasome : a novel drug target for autoimmune diseases

Lade...
Vorschaubild
Dateien
Zu diesem Dokument gibt es keine Dateien.
Datum
2015
Herausgeber:innen
Kontakt
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
URI (zitierfähiger Link)
DOI (zitierfähiger Link)
ArXiv-ID
Internationale Patentnummer
EU-Projektnummer
DFG-Projektnummer
Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Gesperrt bis
Titel in einer weiteren Sprache
Forschungsvorhaben
Organisationseinheiten
Zeitschriftenheft
Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published
Erschienen in
Clinical and Experimental Rheumatology. 2015, 33(4, Suppl. 92), pp. S74-S79. ISSN 1593-098X
Zusammenfassung

The immunoproteasome, a special class of the proteasome, is mainly expressed in cells of haematopoietic origin. Additionally, during inflammation, the immunoproteasome is induced by IFN-γ or TNF-α. In recent years it became apparent that the immunoproteasome has important functions other than processing proteins for MHC class I restricted presentation. The immunoproteasome plays a critical role in T cell expansion, cytokine production, and T helper cell differentiation. Inhibition of the immunoproteasome ameliorated disease symptoms in different animal models for autoimmune diseases. Hence, the unique role for LMP7 in controlling pathogenic immune responses provides a therapeutic rationale for targeting LMP7 in autoimmune disorders. In this review we summarise the effect of immunoproteasome inhibition in animal models for rheumatoid arthritis, inflammatory bowel disease, Hashimoto’s thyroiditis, systemic lupus erythematosus, and multiple sclerosis.

Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
570 Biowissenschaften, Biologie
Schlagwörter
immunoproteasome, autoimmune diseases, protein degradation, ubiquitin, proteasome inhibitors
Konferenz
Rezension
undefined / . - undefined, undefined
Zitieren
ISO 690BASLER, Michael, Sarah MUNDT, Annegret BITZER, Christian SCHMIDT, Marcus GRÖTTRUP, 2015. The immunoproteasome : a novel drug target for autoimmune diseases. In: Clinical and Experimental Rheumatology. 2015, 33(4, Suppl. 92), pp. S74-S79. ISSN 1593-098X
BibTex
@article{Basler2015immun-33213,
  year={2015},
  title={The immunoproteasome : a novel drug target for autoimmune diseases},
  number={4, Suppl. 92},
  volume={33},
  issn={1593-098X},
  journal={Clinical and Experimental Rheumatology},
  pages={S74--S79},
  author={Basler, Michael and Mundt, Sarah and Bitzer, Annegret and Schmidt, Christian and Gröttrup, Marcus}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/33213">
    <dcterms:abstract xml:lang="eng">The immunoproteasome, a special class of the proteasome, is mainly expressed in cells of haematopoietic origin. Additionally, during inflammation, the immunoproteasome is induced by IFN-γ or TNF-α. In recent years it became apparent that the immunoproteasome has important functions other than processing proteins for MHC class I restricted presentation. The immunoproteasome plays a critical role in T cell expansion, cytokine production, and T helper cell differentiation. Inhibition of the immunoproteasome ameliorated disease symptoms in different animal models for autoimmune diseases. Hence, the unique role for LMP7 in controlling pathogenic immune responses provides a therapeutic rationale for targeting LMP7 in autoimmune disorders. In this review we summarise the effect of immunoproteasome inhibition in animal models for rheumatoid arthritis, inflammatory bowel disease, Hashimoto’s thyroiditis, systemic lupus erythematosus, and multiple sclerosis.</dcterms:abstract>
    <dc:contributor>Schmidt, Christian</dc:contributor>
    <dc:creator>Bitzer, Annegret</dc:creator>
    <dc:language>eng</dc:language>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/33213"/>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Schmidt, Christian</dc:creator>
    <dc:contributor>Mundt, Sarah</dc:contributor>
    <dc:contributor>Bitzer, Annegret</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2016-03-03T13:58:09Z</dcterms:available>
    <dc:creator>Gröttrup, Marcus</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:title>The immunoproteasome : a novel drug target for autoimmune diseases</dcterms:title>
    <dcterms:issued>2015</dcterms:issued>
    <dc:creator>Basler, Michael</dc:creator>
    <dc:contributor>Gröttrup, Marcus</dc:contributor>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Basler, Michael</dc:contributor>
    <dc:creator>Mundt, Sarah</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2016-03-03T13:58:09Z</dc:date>
  </rdf:Description>
</rdf:RDF>
Interner Vermerk
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Kontakt
URL der Originalveröffentl.
Prüfdatum der URL
Prüfungsdatum der Dissertation
Finanzierungsart
Kommentar zur Publikation
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet